Forest acquisition whets M&A appetite

Share this article:

Actavis's Forest acquisition has piqued industry interest in Teva Pharmaceutical. Bloomberg reports that the Maxim Group thinks that the Actavis move has boosted “prospects that Teva could be acquired next.” Among Maxim's reasons: a new CEO, a shrinking executive board, and a cost-cutting strategy.

Teva would not comment on Bloomberg's story.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions